Abstract 107P
Background
Tumor stroma consists of a complex network of safeguards for tumor proliferation. Tumour stromal imaging using fibroblast-activated protein-tagged radionuclide provides a metabolic-radiological quantum of tumor stromal content. Tumors rich in stroma have been traditionally associated with poorer disease-free outcomes. Our study correlates between standard uptake values (SUV) in fibroblast imaging to tumor stromal ratio evaluated pathologically and the response to radiation therapy in locally advanced carcinoma rectum.
Methods
50 patients of carcinoma Rectum with all patients having undergone cancer associated Fibroblast PET CT scan prior to starting neoadjuvant chemoradiation. Tumors having SUV max > 10 were considered as High. Metabolic activity in tumor site was compared to Tumor stromal ratio and response to radiation was evaluated in histopathological report. Patients were classified into High TSR (<50% Stromal content) and Low Tumor Stroma Ratio (>50% Stromal content).
Results
7 patients who had complete pathological response all had high TSR and SUV mean 20.4. 34 patients had <50% residual disease 67% had high TSR and SUV mean 17.6 and 34% had low TSR and SUV mean of 21.44. 9 patients had >50% residual disease had 77% low TSR and high SUV mean 25.11(Range- 9.51-92.33). Patients with both Low TSR [ >50% stromal content] and SUV Max > 10 have poor pathological response compared to patients with low TSR. In the low stromal content irrespective of SUV the local control was good. Table: 107P
| High TSR | Low TSR | High SUV | Low SUV | |
| Complete response | 7(32%) | 0 | 4(15.4%) | 3(12.5%) |
| <50% Residual disease | 23(71.8%) | 11(61%) | 14(53.8%) | 20(83.3%) |
| >50% Residual disease | 2(6.2%) | 7(39%) | 8(30.8%) | 1(4.2%) |
Conclusions
High Tumor Stromal Ratio showed better complete and partial response to neoadjuvant chemoradiation in locally advanced carcinoma rectum. Tumors with high stromal content were observed to have higher SUV values in fibroblast stromal imaging and the same were also more commonly associated with suboptimal response. The need for dose escalation for the same has to be explored for better tumor control.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract